Biotech companies at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

68 biotech companies are at Festival of Biologics 2026 — 90 presentations on the program and 8 with a booth in the exhibit hall. Most represented: Ichnos Glenmark Innovation (4 on the program), Philochem (4 on the program), Eleva (3 on the program). 32 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–13 of 68 organizations

Organization	Festival of Biologics 2026 Attendance
IG Ichnos Glenmark Innovation New York, NY
	Talk Tue Oct 13 14:50 BEAT®: A Platform to Advance Developable Multispecific Therapeutic Antibodies to the Clinic A platform for building antibodies that grip several targets at once, using a shared light chain and pairing ideas borrowed from T-cell receptors. Chair Wed Oct 14 09:00 Chair's Opening Remarks Keynotes Chair Wed Oct 14 14:05 Chair's Remarks Antibodies for Immunotherapy Talk Wed Oct 14 15:30 BEAT®: A Platform To Advance Developable Multispecific Therapeutic Antibodies To The Clinic Bispecifics & Multispecifics Talk Thu Oct 15 11:40 Analytical approaches for developing clinic ready multispecifics antibodies Antibodies for Immunotherapy
P Philochem Otelfingen, Switzerland
Biotech Philogen's Swiss research subsidiary, developing antibody-cytokine fusions and small-molecule ligands for cancer therapy.	Talk Wed Oct 14 15:10 Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results Antibodies for Immunotherapy Talk Wed Oct 14 17:50 Advancing stable cell line development for production of therapeutic antibodies Comparing random gene insertion with placing genes at chosen spots in the genome to get steadier antibody production from cell lines. Talk Thu Oct 15 09:20 Title TBA Targeting the Tumor Microenvironment Talk Thu Oct 15 11:20 Charge Variants characterization of a noncovalent dimeric fusion protein How to measure the different charged forms of a fusion protein whose two halves are not chemically bonded, unlike a standard antibody.
E Eleva Freiburg, Germany
Biotech Develops biopharmaceuticals produced in moss using its moss-based expression platform.	Chair Wed Oct 14 16:45 Chair's Remarks Protein Engineering Talk Wed Oct 14 17:50 Expression of novel therapeutics through moss-based platforms Alternative Manufacturing Platforms
Transgene
transgene.fr Biotech Develops viral vector-based immunotherapies, including individualized neoantigen cancer vaccines and oncolytic viruses.	Panel Tue Oct 13 12:20 PANEL DISCUSSION: The Next Frontier: Delivering Next-Gen Science for Patients with High Unmet Need Immunotherapy Keynotes · with Novartis, Memorial Sloan Kettering Cancer Center, STAb Therapeutics +1 more Talk Tue Oct 13 14:30 TG4050, a viral-based individualized neoantigen vaccine as adjuvant treatment in head and neck cancer Therapeutic Vaccine Development
MB Memorises Bio
Biotech Therapeutic antibody discovery company spun out of Memo Therapeutics, keeping its DROPZYLLA discovery platform.	Talk Tue Oct 13 16:50 Adaptive trial designs to expedite clinical development Ways to design clinical trials that adapt as data arrive to speed up development, with regulatory lessons and real company examples. Talk Wed Oct 14 11:30 Discovery of novel tumor derived antibody/target pairs for ADC drug development How antibody libraries built from tumors reveal new cancer targets, with early proof that antibody–drug conjugates against them can work. Talk Wed Oct 14 14:10 Title TBA Antibodies for Immunotherapy
M Mabqi
Biotech Develops therapeutic antibodies and antibody-drug conjugates for cancer.	Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 12:10 Next-Generation Tumor-Specific Anti-CD30 ADC as a New Therapy in Hemato-Oncology Armed antibodies Talk Wed Oct 14 12:30 A Novel Pan-Cancer TRPV6-Targeted Therapy Driving Antitumor Activity Through Ion Channel Modulation Why an ion channel that helps tumors grow may be a drug target in many cancers, with lab and animal tests of a therapy.
Anaveon Basel, Switzerland
	Talk Wed Oct 14 17:50 Title TBA Protein Engineering Talk Thu Oct 15 12:00 Title TBA Disease Areas: Inflammation & Autoimmune
EP Ennovate Pharma
	Talk Thu Oct 15 09:00 Title TBA Disease Areas: Inflammation & Autoimmune Chair Thu Oct 15 11:15 Chair's Remarks Disease Areas: Inflammation & Autoimmune
Formycon
	Keynote Tue Oct 13 11:30 From reflection to implementation: streamlined development of biosimilars with pembrolizumab as case study Biosimilars & Late Stage Development Keynote Chair Tue Oct 13 14:05 Chair's Remarks Formulation
KT Kali Therapeutics
	Talk Wed Oct 14 15:30 From Sequence to Clinic in 14 Months: An Accelerated CMC Playbook for TCEs How to speed up manufacturing and quality testing so T cell engagers, antibodies that recruit T cells, reach first human trials sooner. Talk Thu Oct 15 11:40 A novel trispecific antibody for treating autoimmune diseases Disease Areas: Inflammation & Autoimmune
PB Pilatus Biosciences
	Talk Thu Oct 15 09:20 Treating liver disease with novel biologics Disease Areas: Inflammation & Autoimmune Talk Thu Oct 15 11:40 One Metabolic Punch to Tackle Unmet Needs in COPD Translational Medicine
E Etcembly
	Talk Tue Oct 13 15:30 EMLy: Etcembly's AI platform for faster and smarter drug discovery AI & Computational Approaches
Gokyo Biosciences
gokyobio.com Biotech Building a biologics platform and pipeline, starting with immunology biosimilars, to expand access to essential therapies.	Panel Tue Oct 13 17:30 Panel Discussion: Accelerating the Biosimilar Approval Process Regulation · with Targeted Solutions, Parexel, Aretaeus Panel Wed Oct 14 17:30 PANEL DISCUSSION: From Contract to Collaboration: Effective CDMO Strategies for Biopharma Manufacturing How drug makers and contract manufacturers can work as true partners, sharing process know-how and handling changes as production scales up. with OcyonBio, Frost & Sullivan Talk Thu Oct 15 10:00 Engineering Affordability into Biologics: Strategies to Reduce Manufacturing Complexity and COGS Ways to lower the cost of making biologics by planning the molecule, cell line and process together instead of tweaking single steps.